Dogminth 24 g

Hauptinformation

  • Handelsname:
  • Dogminth 24 g Paste zum Einnehmen 7,5 mg/g
  • Dosierung:
  • 7,5 mg/g
  • Darreichungsform:
  • Paste zum Einnehmen
  • Verwenden für:
  • Tiere
  • Art der Medizin:
  • allopathic Droge

Dokumenten

  • Information für medizinisches Fachpersonal:
  • Das Informationsblatt für dieses Produkt ist derzeit nicht verfügbar, können Sie eine Anfrage an unseren Kundendienst zu senden und wir werden Sie benachrichtigen, sobald wir in der Lage, um es zu erhalten.


    Fordern Sie die Packungsbeilage für medizinisches Fachpersonal.

Lokalisierung

  • Erhältlich in:
  • Dogminth 24 g Paste zum Einnehmen 7,5 mg/g
    Belgien
  • Sprache:
  • Deutsch

Weitere Informationen

Status

  • Quelle:
  • AFMPS - Agence Fédérale des Médicaments et des Produits de Santé - Belgium
  • Zulassungsnummer:
  • BE-V105506
  • Letzte Änderung:
  • 17-04-2018

Packungsbeilage

Leaflet – Version DE

DOGMINTH 16 G

GEBRAUCHSINFORMATION

DOGMINTH

1.

NAME

UND

ANSCHRIFT

DES

ZULASSUNGSINHABERS

UND,

WENN

UNTERSCHIEDLICH, DES HERSTELLERS, DER FÜR DIE CHARGENFREIGABE

VERANTWORTLICH IST

Zulassungsinhaber, der Für die Chargenfreigabe verantwortlicher Hersteller:

Zoetis Belgium SA

Rue Laid Burniat, 1

B-1348 Louvain-la-Neuve

2.

BEZEICHNUNG DES TIERARZNEIMITTELS

DOGMINTH

3.

WIRKSTOFF(E) UND SONSTIGE BESTANDTEILE

Pyranteli embonas (= pyrantelum 7,5 mg) - Natr. alginas - Sorbitol. 70 % non cristallisabile - Silica

colloidalis anhydrica - Methyl. parahydroxybenzoas - Propyl. parahydroxybenzoas - Aqua purificata ad

1 g.

4.

ANWENDUNGSGEBIET(E)

Dogminth dient der Behandlung von Verwurmungen im Magen-Darm-Trakt des Hundes, die von

Nematoden wie Toxocara canis, Toxascaris leonina und Uncinaria stenocephala hervorgerufen

werden.

5.

GEGENANZEIGEN

Es sind keinerlei Gegenanzeigen bekannt.

6.

NEBENWIRKUNGEN

Es wurden keinerlei Nebenwirkungen beobachtet.

7.

ZIELTIERART(EN)

Hunden.

8.

DOSIERUNG FÜR JEDE TIERART, ART UND DAUER DER ANWENDUNG

Dogminth wird einmalig oral verabreicht.

Die Dosis beträgt 5 mg Pyrantelbase je kg Lebendgewicht.

Behandlungsschema :

Es wird angeraten,

- die Welpen: ab dem Alter von 2 bis 4 Wochen sowie im Alter von 7–8 und 12 Wochen.

- die Hündinnen: unmittelbar vor oder nach dem Decken und unmittelbar vor dem Werfen.

- die anderen Hunde: mindestens einmal im Jahr zu entwurmen.

Das hier empfohlene Behandlungsschema ist eine Beispiel-Dosierung.

9.

HINWEISE FÜR DIE RICHTIGE ANWENDUNG

Dogminth Spritzen mit 16 g:

Die Menge der zu verabreichenden Paste muss entsprechend der auf der Spritze aufgedruckten

Gewichtsskala an das Gewicht des Tieres angepasst werden.

Leaflet – Version DE

DOGMINTH 16 G

Dogminth Tube 24 g:

Bei einfacher Druckausübung auf die Tube quillt die Paste in einem Strang heraus; je kg

Lebendgewicht sind 2 cm Paste (entspricht einer Dosis von 5 mg Pyrantelbase je kg Lebendgewicht)

zu verwenden. Die Menge der zu verabreichenden Paste wird mit Hilfe der auf der Schachtel

aufgedruckten Skala bestimmt.

Die für eine Behandlung benötigte Pastenmenge kann direkt auf die Zunge des Tieres gegeben oder

unter die Nahrung gemischt werden.

Spezielle Vorkehrungen bezüglich Futtermittel sind im Vorfeld nicht erforderlich.

Dogminth kann gefahrlos für Hunde aller Altersklassen eingesetzt werden und wird von den Welpen

gut vertragen, auch bei wiederholter Anwendung.

10.

WARTEZEIT

Nicht zutreffend.

11.

BESONDERE LAGERUNGSHINWEISE

Der Spritzen vor Licht schützen.

Haltbarkeit des Tierarzneimittels im unversehrten Behältnis: 3 Jahre

12.

BESONDERE WARNHINWEISE

- Die

Arzneimittel

verabreichenden

Personen

brauchen

keine

besonderen

Sicherheitsvorkehrungen zu treffen.

- Die Verabreichung von Dogminth an trächtige oder säugende Hündinnen ist ohne Bedenken

möglich.

- Zusätzlich zu den unter Punkt 4 beschriebenen Indikationen - wo jedoch die Parasiten nicht

endemisch in Belgien und Luxemburg sind - sollte beachtet werden, dass Dogminth ebenfalls zur

Behandlung

gastro-intestinaler

Krankheiten,

verursacht

durch Ancylostoma

caninum

Ancylostoma braziliense, angezeigt ist.

13.

BESONDERE VORSICHTSMASSNAHMEN FÜR DIE ENTSORGUNG VON NICHT

VERWENDETEM ARZNEIMITTEL ODER VON ABFALLMATERIALIEN, SOFERN

ERFORDERLICH

Es sind geeignete Vorsichtmaßnahmen zu treffen, damit das Produkt nicht in die Umwelt gelangt.

Leaflet – Version DE

DOGMINTH 16 G

14.

GENEHMIGUNGSDATUM DER PACKUNGSBEILAGE

Mai 2014.

15.

WEITERE ANGABEN

BE-V164096 (Spritze von 16 g)

BE-V105506 (Tube von 24 g)

Nicht verschreibungspflichtig

25-7-2018

AMPI Recalls Limited Amount of Dry Whey Powder Because of Possible Health Risk

AMPI Recalls Limited Amount of Dry Whey Powder Because of Possible Health Risk

Associated Milk Producers Inc. (AMPI) of New Ulm, Minn., is recalling dry whey powder packaged in 50-pound and 25-kg bags that were produced at the cooperative’s Blair, Wis., dry whey plant from May 1-5, 2018; May 24-29, 2018; June 2-5, 2018; and June 7-14, 2018 due to the potential to be contaminated with Salmonella. This is a precautionary recall. All products shipped to the marketplace tested negative for Salmonella.

FDA - U.S. Food and Drug Administration

14-7-2018

Dringende Sicherheitsinformation zu MagNA Pure 24 System von Roche Diagnostics GmbH

Dringende Sicherheitsinformation zu MagNA Pure 24 System von Roche Diagnostics GmbH

Weitere Informationen sowie Details zum Produkt entnehmen Sie bitte der anliegenden Kundeninformation des Herstellers.

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

7-3-2018

Cerenia 24 mg ad us. vet., Tabletten

Cerenia 24 mg ad us. vet., Tabletten

● Änderung Text "Dosierung / Anwendung" (Reisekrankheit) ● Änderung Text "Sonstige Hinweise"

Institut für Veterinärpharmakologie und toxikologie

24-1-2018

Enforcement Report for the Week of January 24, 2018

Enforcement Report for the Week of January 24, 2018

FDA - U.S. Food and Drug Administration

30-11-2016

Twelve new substances on the list of euphoriant substances

Twelve new substances on the list of euphoriant substances

As of 24 November 2016, 12 new substances are included in the Danish executive order no. 557 of 31 May 2011 on euphoriant substances issued by the Danish Ministry of Health. The information is primarily relevant to companies authorised to deal with euphoriant substances.

Danish Medicines Agency

3-10-2014

Consultation procedure about medicinal products and safety measure requirements not completed yet

Consultation procedure about medicinal products and safety measure requirements not completed yet

On 5 September 2014, the Danish Health and Medicines Authority submitted a draft list of the medicinal products comprised by the new safety measures rules (Directive 2001/83) for consultation. The consultation period expired on 17 September 2014, and on 3 October we were to inform the European Commission of the medicinal products we recommend including in the common EU lists. We have received 22 consultation responses. But on 24 September 2014 the European Commission amended the original guideline for...

Danish Medicines Agency

31-7-2012

Danish Pharmacovigilance Update, 24 May 2012

Danish Pharmacovigilance Update, 24 May 2012

Among the topics covered in this issue of Danish Pharmacovigilance Update are: Drug Analysis Prints involving data from more than 14,000 Danish adverse reaction reports available at the Danish Health and Medicines Authority’s website.

Danish Medicines Agency

17-8-2018

 Minutes of the COMP meeting of 22-24 May 2018

Minutes of the COMP meeting of 22-24 May 2018

Europe - EMA - European Medicines Agency

14-8-2018

Neupro® 2 mg/24 h

Rote - Liste

7-8-2018

Inlyta (Pfizer Europe MA EEIG)

Inlyta (Pfizer Europe MA EEIG)

Inlyta (Active substance: Axitinib) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5429 of Tue, 07 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2406/T/24

Europe -DG Health and Food Safety

2-8-2018

Leganto® 1 mg/24 h // 3 mg/24 h

Rote - Liste

2-8-2018

Leganto® 2 mg/24 h

Rote - Liste

1-8-2018

Pregabalin Pfizer (Pfizer Limited)

Pregabalin Pfizer (Pfizer Limited)

Pregabalin Pfizer (Active substance: pregabalin) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5234 of Wed, 01 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3880/T/24

Europe -DG Health and Food Safety

24-7-2018

Agenda:  Agenda - PDCO agenda of the 24-27 July 2018 meeting

Agenda: Agenda - PDCO agenda of the 24-27 July 2018 meeting

Europe - EMA - European Medicines Agency

23-7-2018

Agenda:  Agenda - HMPC agenda of the 23-24 July 2018 meeting

Agenda: Agenda - HMPC agenda of the 23-24 July 2018 meeting

Europe - EMA - European Medicines Agency

10-7-2018

 Minutes - PDCO minutes of the 24-27 April 2018 meeting

Minutes - PDCO minutes of the 24-27 April 2018 meeting

Europe - EMA - European Medicines Agency

10-7-2018

Nicotinell®/24-Stunden-Pflaster

Rote - Liste

11-6-2018

Zykadia (Novartis Europharm Limited)

Zykadia (Novartis Europharm Limited)

Zykadia (Active substance: ceritinib) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3758 of Mon, 11 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3819/T/24

Europe -DG Health and Food Safety

28-5-2018

Vipdomet (Takeda Pharma A/S)

Vipdomet (Takeda Pharma A/S)

Vipdomet (Active substance: alogliptin / metformin) - Centralised - Renewal - Commission Decision (2018)3346 of Mon, 28 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2654/R/24

Europe -DG Health and Food Safety

24-5-2018

#ThrowBackThursday- May 24, 1977- Bureau of Medical Devices and Diagnostic Products renamed Bureau of Medical Devices and new Office of Small Manufacturers Assistance created, as required by law. #OnThisDay #FDAHistory

#ThrowBackThursday- May 24, 1977- Bureau of Medical Devices and Diagnostic Products renamed Bureau of Medical Devices and new Office of Small Manufacturers Assistance created, as required by law. #OnThisDay #FDAHistory

#ThrowBackThursday- May 24, 1977- Bureau of Medical Devices and Diagnostic Products renamed Bureau of Medical Devices and new Office of Small Manufacturers Assistance created, as required by law. #OnThisDay #FDAHistory

FDA - U.S. Food and Drug Administration

24-5-2018

Tybost (Gilead Sciences International Limited)

Tybost (Gilead Sciences International Limited)

Tybost (Active substance: cobicistat) - PSUSA - Modification - Commission Decision (2018)3255 of Thu, 24 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/10081/201708

Europe -DG Health and Food Safety

24-5-2018

Ultibro Breezhaler (Novartis Europharm Limited)

Ultibro Breezhaler (Novartis Europharm Limited)

Ultibro Breezhaler (Active substance: indacaterol/glycopyrronium bromide) - Centralised - Renewal - Commission Decision (2018)3259 of Thu, 24 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2679/R/24

Europe -DG Health and Food Safety

24-5-2018

Jylamvo (Therakind Ltd)

Jylamvo (Therakind Ltd)

Jylamvo (Active substance: methotrexate) - PSUSA - Modification - Commission Decision (2018)3263 of Thu, 24 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/2014/201706

Europe -DG Health and Food Safety

24-5-2018

Pemetrexed Krka (KRKA, d.d., Novo mesto)

Pemetrexed Krka (KRKA, d.d., Novo mesto)

Pemetrexed Krka (Active substance: pemetrexed) - Centralised - Authorisation - Commission Decision (2018)3278 of Thu, 24 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3958

Europe -DG Health and Food Safety

24-5-2018

Osseor (Les Laboratoires Servier)

Osseor (Les Laboratoires Servier)

Osseor (Active substance: Strontium ranelate) - PASS - Modification - Commission Decision (2018)3271 of Thu, 24 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSR/S/13

Europe -DG Health and Food Safety

24-5-2018

Protelos (Les Laboratoires Servier)

Protelos (Les Laboratoires Servier)

Protelos (Active substance: Strontium ranelate) - PASS - Modification - Commission Decision (2018)3270 of Thu, 24 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSR/S/13

Europe -DG Health and Food Safety

24-5-2018

Ristaben (Merck Sharp and Dohme Limited)

Ristaben (Merck Sharp and Dohme Limited)

Ristaben (Active substance: sitagliptin) - PSUSA - Modification - Commission Decision (2018)3258 of Thu, 24 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/2711/201708

Europe -DG Health and Food Safety

24-5-2018

Velmetia (Merck Sharp and Dohme Limited)

Velmetia (Merck Sharp and Dohme Limited)

Velmetia (Active substance: sitagliptin / metformin hydrochloride) - PSUSA - Modification - Commission Decision (2018)3261 of Thu, 24 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/2003/201708

Europe -DG Health and Food Safety

24-5-2018

Ristfor (Merck Sharp and Dohme Limited)

Ristfor (Merck Sharp and Dohme Limited)

Ristfor (Active substance: sitagliptin / metformin hydrochloride) - PSUSA - Modification - Commission Decision (2018)3262 of Thu, 24 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/2003/201708

Europe -DG Health and Food Safety

24-5-2018

Janumet (Merck Sharp and Dohme Limited)

Janumet (Merck Sharp and Dohme Limited)

Janumet (Active substance: sitagliptin / metformin hydrochloride) - PSUSA - Modification - Commission Decision (2018)3260 of Thu, 24 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/2003/201708

Europe -DG Health and Food Safety

24-5-2018

Efficib (Merck Sharp and Dohme Limited)

Efficib (Merck Sharp and Dohme Limited)

Efficib (Active substance: sitagliptin / metformin hydrochloride) - PSUSA - Modification - Commission Decision (2018)3276 of Thu, 24 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/2003/201708

Europe -DG Health and Food Safety

24-5-2018

Bosulif (Pfizer Limited)

Bosulif (Pfizer Limited)

Bosulif (Active substance: Bosutinib) - Centralised - Variation - Commission Decision (2018)3269 of Thu, 24 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2373/X/26

Europe -DG Health and Food Safety

24-5-2018

Xoterna Breezhaler (Novartis Europharm Limited)

Xoterna Breezhaler (Novartis Europharm Limited)

Xoterna Breezhaler (Active substance: indacaterol/glycopyrronium bromide) - Centralised - Renewal - Commission Decision (2018)3265 of Thu, 24 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3755/R/27

Europe -DG Health and Food Safety

24-5-2018

Stivarga (Bayer AG)

Stivarga (Bayer AG)

Stivarga (Active substance: regorafenib) - Centralised - Renewal - Commission Decision (2018)3266 of Thu, 24 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2573/R/25

Europe -DG Health and Food Safety

24-5-2018

Tesavel (Merck Sharp and Dohme Limited)

Tesavel (Merck Sharp and Dohme Limited)

Tesavel (Active substance: sitagliptin) - PSUSA - Modification - Commission Decision (2018)3256 of Thu, 24 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/2711/201708

Europe -DG Health and Food Safety

24-5-2018

Pedea (Orphan Europe S.A.R.L.)

Pedea (Orphan Europe S.A.R.L.)

Pedea (Active substance: Ibuprofen) - PSUSA - Modification - Commission Decision (2018)3257 of Thu, 24 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/1712/201707

Europe -DG Health and Food Safety

24-5-2018

Stribild (Gilead Sciences International Limited)

Stribild (Gilead Sciences International Limited)

Stribild (Active substance: elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil (as fumarate)) - PSUSA - Modification - Commission Decision (2018)3277 of Thu, 24 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2574/PSUSA/10082/201708

Europe -DG Health and Food Safety

24-5-2018

Xarelto (Bayer AG)

Xarelto (Bayer AG)

Xarelto (Active substance: rivaroxaban) - Centralised - Renewal - Commission Decision (2018)3264 of Thu, 24 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/944/R/60

Europe -DG Health and Food Safety

24-5-2018

Xelevia (Merck Sharp and Dohme Limited)

Xelevia (Merck Sharp and Dohme Limited)

Xelevia (Active substance: sitagliptin) - PSUSA - Modification - Commission Decision (2018)3275 of Thu, 24 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/762/PSUSA/2711/20178

Europe -DG Health and Food Safety

24-5-2018

Tyverb (Novartis Europharm Limited)

Tyverb (Novartis Europharm Limited)

Tyverb (Active substance: lapatinib) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3273 of Thu, 24 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/795/T/52

Europe -DG Health and Food Safety

22-5-2018

Agenda:  Agenda - COMP agenda of the 22-24 May 2018 meeting

Agenda: Agenda - COMP agenda of the 22-24 May 2018 meeting

Europe - EMA - European Medicines Agency

15-5-2018

Ulunar Breezhaler (Novartis Europharm Limited)

Ulunar Breezhaler (Novartis Europharm Limited)

Ulunar Breezhaler (Active substance: indacaterol/glycopyrronium bromide) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3058 of Tue, 15 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3875/T/24

Europe -DG Health and Food Safety

24-11-2017

Gadolinium

Gadolinium

Gadolinium (Active substance: gadodiamide, gadopentetic acid, gadobenic acid, gadoxetic acid, gadoteridol, gadobutrol and gadoteric acid) - Community Referrals - Art 31 - Commission Decision (2017)7941 of Fri, 24 Nov 2017 European Medicines Agency (EMA) procedure number: EMEA/H/A-31/1437

Europe -DG Health and Food Safety